SecBot SecBot
8-K ·Filed Aug 5, 2026

URGN

UroGen Pharma Ltd.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001437749-26-025793
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The ZUSDURI launch trajectory (73% QoQ growth, 45% repeat prescribers) is the primary catalyst, monitor weekly prescription data and upcoming KOL events for continued acceleration. The EPS miss is minor and likely overshadowed by the revenue beat and patent news. Watch for UGN-103 NDA submission in Q3 2026 as the next major pipeline catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$46.43
T+0 close · Aug 5, 2026 · via day close
Latest settled
−27.89%
T+60 · $33.48
Vs SPY
−27.84%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $46.43entry
  2. T+1 · 3mo ago −1.79%α −1.63% · $45.60
  3. T+5 · 3mo ago +5.54%α +5.18% · $49.00
  4. T+20 · 3mo ago −4.33%α −3.73% · $44.42
  5. T+60 · 19d ago −27.89%α −27.84% · $33.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

UroGen reported Q2 2026 revenue of $72.5M (consensus $63.5M, +14.2% beat), driven by ZUSDURI's $50.4M in revenue (73% QoQ growth). EPS of -$0.28 was a 5.7% miss vs consensus -$0.27. The company raised FY2026 operating expense guidance to $260M-$270M to accelerate ZUSDURI commercialization and pipeline investment. ZUSDURI's accelerating launch trajectory and a new patent allowance extending protection to 2044 are strong positives, but the EPS miss and rising spend temper the outlook.

Key Financial Metrics

EPS
−$0.28
est −$0.27 · -3.7%
Revenue
$72.5M
est $63.5M · +14.1% · +199.2% YoY
Rating
beat
Gross Margin
90.9%

Key Facts

  • Total revenue $72.5M in Q2 2026, up 199% YoY from $24.2M
  • ZUSDURI revenue $50.4M, 73% QoQ growth from Q1 2026
  • EPS -$0.28 vs consensus -$0.27 (5.7% miss)
  • FY2026 operating expense guidance raised to $260M-$270M from $240M-$250M
  • New U.S. patent allowance expected to protect ZUSDURI and UGN-103 into July 2044
  • UGN-103 NDA submission on track for Q3 2026; UGN-501 Phase 1 trial expected Q4 2026
  • Net loss narrowed to $14.4M from $49.9M in Q2 2025
  • Cash and marketable securities $108.0M as of June 30, 2026

Financial Impact

Revenue beat consensus by $9.0M (+14.2%); EPS missed by $0.01 (-5.7%); operating expense guidance raised by $20M at midpoint

revenueepsoperating expensescash

Risk Factors

  • EPS miss vs consensus despite strong revenue beat
  • Rising operating expenses ($260M-$270M guidance) may pressure cash runway
  • JELMYTO revenue declined 9% YoY to $22.0M
  • Teva settlement allows generic JELMYTO entry on September 15, 2030
  • Cash burn: $108.0M at June 30 vs $120.5M at Dec 31, 2025

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-025793
Document: urgn20260730_8k.htm0001437749-26-025793
Document: 0001437749-26-025793-index-headers.html0001437749-26-025793
Document: 0001437749-26-025793-index.html0001437749-26-025793
Document: 0001437749-26-025793.txt0001437749-26-025793
8-K Data (Synthetic)0001437749-26-025793

Track record

16 reports on URGN

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
  2. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 4/10 Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
  6. Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
  7. Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
  9. Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
  10. Aug 5, 202614w ago 8-K Bullish 7/10 Viewing Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026